tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Ross Osborn, 118 are a BUY (91.47%), 11 are a HOLD (8.53%).
Analyst Ross Osborn, currently employed at CANTOR FITZGERALD, carries an average stock price target met ratio of 33.16% that have a potential upside of 46.51% achieved within 113 days.
Ross Osborn’s has documented 250 price targets and ratings displayed on 21 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on LMAT, LeMaitre Vascular at 05-Aug-2025.
Analyst best performing recommendations are on NPCE (NEUROPACE).
The best stock recommendation documented was for NPCE (NEUROPACE) at 5/14/2025. The price target of $17 was fulfilled within 1 day with a profit of $1.4 (8.97%) receiving and performance score of 89.74.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Hold
$1.5
$-0.14 (-8.54%)
$1.25
2 months 14 days ago
(10-Aug-2025)
8/10 (80%)
$0.24 (19.05%)
127
Hold
$1.5
$-0.14 (-8.54%)
$2
4 months ago
(24-Jun-2025)
6/6 (100%)
$0.28 (22.95%)
14
Buy
$1.8
$0.16 (9.76%)
$2.5
5 months 10 days ago
(14-May-2025)
0/3 (0%)
$0.74 (69.81%)
Buy
$3
$1.36 (82.93%)
$4
5 months 16 days ago
(08-May-2025)
1/3 (33.33%)
$1.88 (167.86%)
40
Buy
$3
$1.36 (82.93%)
$3
6 months 15 days ago
(09-Apr-2025)
5/13 (38.46%)
$1.62 (117.39%)
123
Which stock is Ross Osborn is most bullish on?
Which stock is Ross Osborn is most reserved on?
What Year was the first public recommendation made by Ross Osborn?
